Medical/Pharmaceuticals
FONDAZIONE PRADA PRESENTS "HUMAN BRAINS: PRESERVING THE BRAIN - FORUM ON NEURODEGENERATIVE DISEASES"
MILAN, Sept. 6, 2022 /PRNewswire/ -- "Human Brains" is the result of an in-depth research process undertaken by Fondazione Prada in 2018 in the field of neuroscience. The project has featured an online conference dedicated to the study of consciousness, a series of video talks by international sc...
2022-09-06 21:00
4488
Laekna Announces First Patient Dosed in South Korea in LAE201INT2101 Phase 1/2 Study
SHANGHAI and WARREN, N.J., Sept. 6, 2022 /PRNewswire/ -- Laekna, a clinical-stage biotechnology company dedicated to bringing ground-breaking therapies to cancer and liver fibrosis patients worldwide, announced yesterday that the first patient recently received a dose in the LAE201INT2101 phase ...
2022-09-06 17:02
2546
Amcor reveals Lift-Off seed capital winners with investments that seek to "drive the revolution in packaging"
Global packaging leader to provide US $250,000 to two start-ups with cutting edge innovations for a more sustainable future for packaging ZURICH, Sept. 6, 2022 /PRNewswire/ -- Amcor (NYSE: AMCR, ASX: AMC), a global leader in developing and producing responsible packaging solutions, has announced...
2022-09-06 16:10
3981
Jacobio Receives CDE Approval for KRAS G12C Inhibitor JAB-218822's Phase II Pivotal Study in China
BEIJING, SHANGHAI and BOSTON, Sept. 6, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) has received Phase II pivotal study approval of KRAS G12C inhibitor JAB-21822 from the Center for Drug Evaluation (CDE) ofChina in September 5, 2022 . This study aims to treat advanced or metastatic non-small cell...
2022-09-06 15:20
2526
Prospection partners with leading Japanese healthcare data provider Medical Data Vision to improve treatment access for patients
SYDNEY, Sept. 6, 2022 /PRNewswire/ -- Health analytics pioneer, Prospection has announced a unique global data access agreement with leading Japanese medical data company Medical Data Vision Co., Ltd. (MDV) to accelerate healthcare analytics globally. The agreement, covering the world's second...
2022-09-06 07:34
2987
Dizal Announces Sunvozertinib Meets Primary Endpoint in its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO
* The confirmed objective response (cORR), as assessed by blinded independent central review (BICR), was 59.8% in advanced NSCLC with EGFR exon20ins mutations after at least one line of platinum-based chemotherapies * The response rate for patients with baseline brain metastasis was 48.4% * ...
2022-09-05 22:49
3547
Dizal Announces Positive Phase I Clinical Trial Results for DZD1516 in Treating HER2 Breast Cancer at 2022 ESMO
PARIS, Sept. 5, 2022 /PRNewswire/ -- Dizal reported the promising safety and pharmacokinetic data from the global Phase I study ofDZD1516 in patients with HER2 positive metastatic breast cancer (HER2+ MBC) who relapsed from multiple prior treatments at the 2022 European Society for Medical Oncolo...
2022-09-05 22:39
3309
Recruitment opens for Phase II trial in prostate cancer with Cu-64 SAR-Bombesin in the US
SYDNEY, Sept. 5, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the US-based diagn...
2022-09-05 21:09
3456
Lunit to Showcase 5 Abstracts at ESMO 2022
* Lunit to present five posters at ESMO 2022 featuring the company's AI-biomarker platform * Studies corroborate the capability of Lunit SCOPE suite to address an expanding set of clinical and research questions based on world-leading digital pathology AI SEOUL, South Korea, Sept. 5, 2022 /PR...
2022-09-05 21:00
3464
Vernalis Research, a fully owned subsidiary of HitGen Inc., and Unison Medicines Inc. announce a research collaboration in the field of anti-infectives
CHENGDU, China, Sept. 5, 2022 /PRNewswire/ -- Vernalis Research ("Vernalis"), a fully owned subsidiary of HitGen Inc., and Unison Medicines Inc. ("Unison") are pleased to announce a research collaboration on an undisclosed bacterial target. Under the terms of the agreement, Vernalis will use it...
2022-09-05 16:00
3558
Thailand heightens its healthcare hub ambition with integrative medicine
BANGKOK, Sept. 5, 2022 /PRNewswire/ -- Living with the COVID-19 pandemic, people start to recognize the equal importance of modern medicine and preventive practices in maintaining their good health and wellbeing. With a strong healthcare and wellness infrastructure and reputation for highly-skill...
2022-09-05 15:22
5022
Simcere Pharmaceutical Announces Financial Results for 2022 H1: 27% Year-Over-Year Revenue Growth, with Innovative Drugs Accounting for 65.4% of Total Revenue
NANJING, China, Sept. 5, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) announced its financial results for the first half of 2022. As ofJune 30, Simcere recorded operating revenue of RMB 2.7 billion for the first half of the year, with a year-over-year growth of 27.3%. The e...
2022-09-05 13:09
4570
Tamas Oravecz Ph.D. named SVP, CSO of the U.S. of Simcere Pharmaceutical Group
NANJING, China, Sept. 5, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group announces today the appointment ofTamas Oravecz, Ph.D. as Senior Vice President, Chief Scientific Officer of the Simcere U.S. Tamas will be responsible for providing strategic leadership to our drug discovery efforts in A...
2022-09-05 13:08
3612
FDA-approved Investigator-initiated Pre-market Clinical Trial of LAmbre™ Plus LAA Closure System Obtained Medical Insurance Coverage in the US
SHENZHEN, China, Sept. 5, 2022 /PRNewswire/ -- LifeTech Scientific Corporation (Stock Code: 1302.HK) is pleased to announce that on30 August 2022, an FDA-approved investigator-initiated pre-market clinical trial of its proprietary LAmbre™ Plus Left Atrial Appendage (LAA) Closure System has obtai...
2022-09-05 13:02
5988
Docquity raises US$44 million in series C round led by Itochu Corporation
New round of funding to bolster new expansion plans beyond the Southeast Asia region - inNorth Asia and the Middle East SINGAPORE, Sept. 5, 2022 /PRNewswire/ -- Singapore-based Docquity, Southeast Asia's largest community of healthcare professionals, announced today that it has raised a tot...
2022-09-05 10:00
5421
Innovent Announces First Participant Dosed in the Higher-dose Cohort of a Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity
ROCKVILLE, Md. and SUZHOU, China, Sept. 5, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2022-09-05 08:00
4453
Aston Sci. Receives IND Approval from U.S. FDA for Phase 2 Clinical Trial of the Therapeutic Cancer Vaccine AST-301 in Patients with HER2 1+/2+ Breast Cancer
- CornerStone-001(NCT05163223), the multiregional clinical trial for breast cancer treatment, received U.S. FDA approval for Phase 2 trial following the approvals inAustralia and the Taiwan region. - As the same patient group and design of a pivotal study are adopted, a placebo-controlled randomi...
2022-09-05 07:00
2790
LEADERS IN NUTRITIONAL MEDICINE ON CUSP OF BREAKTHROUGH GUIDELINES TO TACKLE LONG-COVID SYMPTOMS
Guidelines for health practitioner diagnosis of Long-COVID are in review Understanding of mitochondrial health integral to post-pandemic recovery, say experts Ninety per cent of people hospitalised with COVID-19 have significant underlying medical conditions, and are more likely to develop Long ...
2022-09-05 04:00
4761
Neukio Biotherapeutics completed Series A-1 financing, to accelerate discovery and development of next generation cell therapy products
SHANGHAI, Sept. 2, 2022 /PRNewswire/ -- Neukio Biotherapeutics, a company committed to developing novel cell therapy products, announces it has closed $50 million in a Series A-1 funding round. The investment round was led by CD Capital, with the participation of Alwin Capital and Surplus Capital...
2022-09-02 20:50
4446
Jacobio Completes First Patient Dosage of CD73 mAb JAB-BX102 in China
BEIJING, Sept. 2, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced it has completed first patient dosage of it's in-house R&D drug candidate CD73 monoclonal antibody JAB-BX102 in a Phase I/IIa clinical trial for advanced solid tumour patients. This is a phase I/IIa multi-center, open-la...
2022-09-02 19:00
3140
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 310 media titles]
2026-10-27 13:40
Hong Leong Bank Strengthens Cross-Border Payment Connectivity through Partnership with UnionPay International
[Picked up by 294 media titles]
2026-10-28 12:12
Agoda becomes first travel platform regionally to seamlessly connect with Meta's Muse
[Picked up by 294 media titles]
2026-10-28 09:00
OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW
[Picked up by 277 media titles]
2026-10-28 09:00
Pepperstone and Aston Martin Aramco extend and expand partnership with Fernando Alonso appointed Global Ambassador from 2027.
[Picked up by 276 media titles]
2026-10-29 13:01
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
52348
SwitchBot Launches AI Art Frame 2 with Full-Color E Ink and Personalized Art
2026-10-27 21:00
51309
